Alluvi, known as BI 4744, represents a notable advance in obesity treatment. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable efficacy in https://thebookpage.com/story7632206/alluvi-a-detailed-examination-into-the-medication-s-prospects